Stifel Financial Corp Quietly Rotates From U.S. Megacaps to Broad Growth

Stifel’s biggest dollar add was not another AI darling but AbbVie: they lifted the stake by +51.2%, adding about $275.0M and taking it to 0.75% of the book. That move, alongside steady positions in Eli Lilly, Merck, and Amgen, reads as a deliberate overweight to large-cap pharma where earnings power is tangible and less macro‑sensitive.

The other big story is the quiet but firm embrace of growth beta via ETFs. Instead of pushing Microsoft or Meta weights higher, Stifel used Invesco QQQ, iShares S&P 500 Growth (IVW), and iShares Core S&P 500 (IVV) as scalable ways to stay long U.S. growth without adding single‑name event risk.

Their top incremental capital deployments clustered in:

• AbbVie: scaling a high-cash-flow pharma name as a health‑care core.
• QQQ and IVW: adding diversified exposure to the same factor complex as their megacap tech book.
• IEFA and VOO: modest but clear reinforcement of broad developed‑market and S&P 500 exposure.
• APD and NFLX: selective adds to industrial chemicals and consumer streaming, hinting at confidence in industrial capex and digital consumer spend.

Taken together, the buying pattern says Stifel still wants growth and earnings momentum — but increasingly via diversified vehicles and a few targeted conviction names, not just the FAANG+ complex.

On the sell side, the standout message is in Walmart: Stifel cut the position by -65.2%, freeing roughly $788.0M in estimated capital and shrinking it to 0.39% of the portfolio. That is not a routine trim; it’s a decisive step back from U.S. big‑box retail as a core defensive.

They also systematically shaved high‑flying tech winners — Nvidia, Microsoft, Apple, Alphabet, and Meta all saw low‑single‑digit share cuts. Given the enormous embedded gains (Nvidia up over 2,400% versus their average cost, Apple over 500%), these look like risk and position-size management, not a repudiation of AI or cloud.

Other notable funding sources:

• Johnson & Johnson: an -8.5% trim, dialing back a classic low‑vol health‑care stalwart as they lean into higher‑beta pharma like AbbVie.
• Exxon and Chevron: mid‑single‑digit cuts, signaling less urgency around riding the energy cycle at this stage.
• Cummins and Union Pacific: reductions in cyclical industrial and freight exposure, consistent with a more growth‑and‑quality‑tilted stance.
• VEA: a -10.1% cut to developed ex‑U.S. value exposure, used to help fund their growth and U.S.‑centric reallocations.

The pattern is consistent: harvest outsized and cyclical winners, plus some low‑octane defensives, to bankroll a more growth‑centric, ETF‑heavy portfolio architecture.

Under the hood, Stifel’s sector rotation is incremental but telling. Technology’s share of the book inched up from 35.14% to 35.32%, despite trimming every top single-stock tech winner; the lift comes via adds to QQQ, IVW, and smaller hardware and components plays like Texas Instruments, Eaton, and Amphenol.

Consumer exposure, by contrast, is being pared back. Consumer discretionary fell from 14.74% to 13.28%, driven largely by the Walmart reduction and modest trims in Costco and TJX, even as they added to Netflix and held Home Depot — a shift from brick-and-mortar giants toward more asset-light and digital discretionary names.

Health care rose from 10.30% to 10.85%, almost entirely on the back of the AbbVie build, nudging the sector closer to a true core alongside tech. Energy slipped from 3.01% to 2.95% and industrials from 4.02% to 3.95%, reflecting those trims in Exxon, Chevron, Cummins, and Union Pacific.

They also marginally increased their “unclassified” ETF and cash-like sleeve from 18.65% to 19.27%. That bucket includes broad equity ETFs and the BIL T‑bill fund, which together point to a structurally larger allocation to systematic beta and liquidity as markets grind higher.

Stifel’s 13F does not read like a manager calling the top in AI or U.S. equities. Instead, it looks like a house that wants to stay long structural growth but with less single‑name risk and more ballast from health care and broad ETFs.

The big AbbVie add and the small upgrades in Merck‑adjacent pharma exposure indicate a belief that drug pipelines and pricing power can complement their tech engines as core earnings drivers. Simultaneously, shifting capital from Walmart, energy, and cyclical industrials into QQQ, IVW, and APD suggests they see more attractive risk‑adjusted upside in growth and industrial‑adjacent infrastructure than in late‑cycle consumer or commodity plays.

The rising ETF and T‑bill sleeve points to an institutional preference for scalability and optionality. If volatility returns, this book now has more liquid, diversified pieces they can scale up or down quickly, rather than being hostage to five or six megacap stories.

For observers, the forward read is straightforward: expect Stifel to keep technology and health care as twin pillars, with incremental tweaks around the edges as macro conditions evolve. The real pivot worth watching isn’t sector-level; it’s their continued migration from stock‑picking around a few icons toward factor and index expressions of the same underlying growth thesis.